1. Collins, PW, Hirsch, S, Baglin, TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007; 109: 1870–1877.
Google Scholar | Crossref | Medline | ISI2. Tiede, A, Collins, P, Knoebl, P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 2020; 105: 1791–1801.
Google Scholar | Crossref | Medline3. Tiede, A, Klamroth, R, Scharf, RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015; 125: 1091–1097.
Google Scholar | Crossref | Medline4. Baudo, F, Collins, P, Huth-Kuehne, A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120: 39–46.
Google Scholar | Crossref | Medline | ISI5. Oldenburg, J, Mahlangu, JN, Kim, B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809–818.
Google Scholar | Crossref | Medline | ISI6. Mahlangu, J, Oldenburg, J, Paz-Priel, I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379: 811–822.
Google Scholar | Crossref | Medline7. Shima, M, Hanabusa, H, Taki, M, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv 2017; 1: 1891–1899.
Google Scholar | Crossref | Medline8. Dane, KE, Lindsley, JP, Streiff, MB, et al. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost 2019; 3: 420–423.
Google Scholar | Crossref | Medline9. Möhnle, P, Pekrul, I, Spannagl, M, et al. Emicizumab in the treatment of acquired haemophilia: a case report. Transfus Med Hemother 2019; 46: 121–123.
Google Scholar | Crossref | Medline10. Al-Banaa, K, Alhillan, A, Hawa, F, et al. Emicizumab use in treatment of acquired hemophilia A: a case report. Am J Case Rep 2019; 20: 1046–1048.
Google Scholar | Crossref | Medline11. Knoebl, P, Thaler, J, Jilma, P, et al. Emicizumab for the treatment of acquired hemophilia A. Blood 2021; 137: 410–419.
Google Scholar | Crossref | Medline12. Chen, EC, Gibson, WJ, Temoczko, P, et al. Treatment of acquired hemophilia a with rituximab and emicizumab. Blood 2020; 136(Suppl. 1): 18–19.
Google Scholar | Crossref13. Borg, JY, Guillet, B, Le Cam-Duchez, V, et al. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l’Hémophilie Acquise) Registry. Haemophilia 2013; 19: 564–570.
Google Scholar | Crossref | Medline14. Knoebl, P, Marco, P, Baudo, F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10: 622–631.
Google Scholar | Crossref | Medline | ISI15. Batty, P, Moore, GW, Platton, S, et al. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. Thromb Haemost 2015; 114: 804–811.
Google Scholar | Crossref | Medline16. Takeyama, M, Nogami, K, Matsumoto, T, et al. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A. J Thromb Haemost 2020; 18: 825–833.
Google Scholar | Crossref | Medline17. Holstein, K, Liu, X, Smith, A, et al. Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study. Blood 2020; 136: 279–287.
Google Scholar | Medline18. Tiede, A, Kemkes-Matthes, B, Knöbl, P. Should emicizumab be used in patients with acquired hemophilia A? J Thromb Haemost 2021; 19: 637–644.
Google Scholar | Crossref | Medline